Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
PRE 14A
Preliminary proxy
19 Apr 24
8-K
Departure of Directors or Certain Officers
21 Mar 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
12 Mar 24
8-K
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
24 Jan 24
8-K
Entry into a Material Definitive Agreement
11 Jan 24
8-K
Other Events
22 Dec 23
8-K
Departure of Directors or Certain Officers
21 Dec 23
8-K
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
424B3
Prospectus supplement
5 Sep 23
EFFECT
Notice of effectiveness
1 Sep 23
CORRESP
Correspondence with SEC
30 Aug 23
UPLOAD
Letter from SEC
28 Aug 23
S-3
Shelf registration
23 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates
14 Aug 23
D
$30.00 mm in equity / options, sold $30.00 mm, 7 investors
1 Aug 23
8-K
Heron Therapeutics Announces $30 Million Private Placement Financing
24 Jul 23
S-8
Registration of securities for employees
30 Jun 23
8-K
Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer
23 Jun 23
8-K
Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer
12 Jun 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Net Product Sales for First Quarter of 2023 Grew 26% to $29.6 million, Compared to First Quarter Net Product Sales in 2022
11 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
DEF 14A
Definitive proxy
1 May 23
PRE 14A
Preliminary proxy
20 Apr 23
8-K
Heron Therapeutics Announces Commercial Leadership Changes
20 Apr 23
8-K
Heron Therapeutics Announces New CEO and Board Chairman
3 Apr 23
10-K
2022 FY
Annual report
29 Mar 23
8-K
Results of Operations and Financial Condition
23 Mar 23
8-K
Other Events
13 Mar 23
8-K
Heron Therapeutics Announces U.S. Commercial Launch of APONVIETM for the Management of Postoperative Nausea and Vomiting in Adults
6 Mar 23
8-K
Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan Capital
22 Feb 23
8-K
Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises
9 Jan 23
8-K
Other Events
29 Dec 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Results of Operations and Financial Condition
8 Nov 22
Latest ownership filings
4
Ira Duarte
19 Apr 24
4
William P Forbes
19 Apr 24
4
Craig A Collard
19 Apr 24
4
Craig A Collard
5 Apr 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
FRANKLIN RESOURCES INC
6 Feb 24
4
Waage Christian
19 Jan 24
4
Susan Rodriguez
19 Jan 24
4
Adam Morgan
19 Jan 24
4
Craig A Johnson
19 Jan 24
4
Sharmila Dissanaike
19 Jan 24
4
Lisa Peraza
19 Jan 24
4
William P Forbes
19 Jan 24
4
Ira Duarte
19 Jan 24
4
Craig A Collard
19 Jan 24
4
Lisa Peraza
16 Jan 24
SC 13G/A
JPMORGAN CHASE & CO
7 Dec 23
SC 13G/A
BlackRock Inc.
6 Dec 23
4
William P Forbes
21 Nov 23
4
William P Forbes
20 Nov 23
4
Craig A Collard
17 Nov 23
4
Ira Duarte
17 Nov 23
4
Lisa Peraza
17 Oct 23
4
Craig A Collard
24 Aug 23
4
Adam Morgan
25 Jul 23
3
David Efraim Rosen
25 Jul 23
SC 13D/A
Rubric Capital Management LP
25 Jul 23
4
Lisa Peraza
19 Jul 23
4
David Leslie Szekeres
17 Jul 23
4
Lisa Peraza
17 Jul 23
3
Ira Duarte
23 Jun 23
3
William P Forbes
12 Jun 23
4
Craig A Collard
24 May 23
4
David Leslie Szekeres
17 Apr 23
4
JOHN POYHONEN
17 Apr 23
4
Lisa Peraza
17 Apr 23
4
KIMBERLY MANHARD
17 Apr 23